The effect of natural killer cells level in bone marrow on the prognosis of patients with acute myeloid leukemia
-
摘要: 目的：探讨骨髓自然杀伤(natural killer,NK)细胞水平对急性髓细胞性白血病(acute myeloid leukemia,AML)患者预后的影响。方法：研究分成AML初治组40例,缓解组20例,正常对照组20例。均抽取骨髓液2 ml,采用直接免疫荧光标记法对骨髓有核细胞进行单克隆抗体(CD16+/CD56+)标记,应用流式细胞仪进行NK细胞数量的检测。结果:初治组患者骨髓NK细胞表达水平较缓解组显著降低(P0.01)。缓解组患者骨髓NK细胞表达水平仍低于对照组(P0.05)。不同骨髓NK细胞表达水平间原始细胞数量和AML患者疗效差异均有统计学意义(P0.01和P0.05)。结论：骨髓NK细胞表达水平可以作为AML的预后指标,亦有助于指导治疗。Abstract: Objective: To explore the effects of natural killer (NK) cells in bone marrow on the prognosis of patients with acute myeloid leukemia(AML). Methods: Sixty patients with AML were divided into original treating group(40 cases) and remission group (20 cases), 20 health people were served as control group． The CD16 + /CD56 + of monoclonal antibodies in bone marrow nucleatedcells of three groups were detected by direct immunofluorescence labeling method， the levels of NK cells were determined with flowcytometry． Results: The levels of NK in original treating group were significantly lower than those in remission group(P ＜ 0． 01), the levels of NK in remission group were significantly lower than those in normal group(P ＜ 0． 05). The original cell number in different NK cell levels and the differences of curative effect in AML patients were statistically significant(P ＜ 0． 01 and P ＜ 0． 05). Conclusions:The level of NK cells in bone marrow is a prognostic index of AML and can help to guide treatment．
-
Keywords:
- acute myeloid leukemia /
- natural killer cells /
- prognosis
-
-
[1] [2] Hoskin PJ，Hanks GW.Opioid agonist-antagonist drugs in acuteand chronic pain states[J].Drugs，1991，41(3) : 326 - 344.
[1] 岳修勤.地佐辛与芬太尼用于术后静脉镇痛的临床效果比较[J].中国疼痛医学杂志，2010，16(4) : 255 - 256. [2] [3] 庄心良，曾因明，陈伯銮.现代麻醉学[M].3 版.北京: 人民卫生出版社，2003: 514 - 515. [3] [4] Fischer BD，Dykstra LA.Interactions between an N-methly-Dasparteantagonist and low-efficacy opioid receptor agonists inassays of schedule-controlled Responding And Thermal nociceptionExp[J].J Pharmacol Ther，2006，318(3) : 1300 - 1306.
[4] [5] Fukuda K.Opioids [M]//Miller RD.Anesthesia.7th ed.Philadelphia: Churchill Livingstone，2010: 769 - 824.
[5] [6] Prasad Verma PR，Chandak AR.Development of matrix controlledtransdermal delivery systems of pentazocine: in vitro/in vivoperformance[J].Acta Pharm，2009，59(20) : 171 - 186.
[6] [7] 邱小弟，余守章，黄焕林.喷他佐辛临床镇痛的应用研究进展[J].广东医学，2010，31(10) : 1218 - 1220.
计量
- 文章访问数: 3484
- HTML全文浏览量: 368
- PDF下载量: 107
下载:
